Brookfield Corp’s Relmada Therapeutics RLMD Stock Holding History

Brookfield Corp’s Portfolio RLMD Stock Details RLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-11,812	Closed	-$437K	–	722
2022 Q3	$437K	Buy	+11,812	New	+$327K	﹤0.01%	578

Other funds holding RLMD

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

PCM

Parsons Capital Management Providence, Rhode Island $2.21B AUM 28.12% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Brookfield Corp's RLMD Position: Q4 2022 in Review

Brookfield Corp sold out of Relmada Therapeutics (RLMD) in Q4 2022, closing a stake of 11,812 shares — an estimated $437K sold.

Brookfield Corp first reported a position in RLMD in Q3 2022 and held it in 1 quarter. The position peaked at $437K in Q3 2022. 109 funds tracked by Wall St. Rank hold RLMD as of Q4 2022.

Brookfield Corp reported no remaining Relmada Therapeutics position as of Q4 2022 after selling out during the quarter.
Brookfield Corp sold 11,812 Relmada Therapeutics shares in Q4 2022, an estimated $437K.
Brookfield Corp first reported a position in Relmada Therapeutics in Q3 2022 and held it in 1 quarter.
Brookfield Corp's Relmada Therapeutics position peaked at $437K in Q3 2022.
109 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q4 2022.

Based on Brookfield Corp's 13F filing for Q4 2022, filed 14 Feb 2023.